The article examines the objective, findings, and clinical context described in Acute Myelopathy After CAR T-Cell Therapy: A Rare Diagnostic Dilemma.
Approach:
Infection assessment: In profoundly immunocompromised patients, infectious myelitis—particularly viral causes—should be excluded. In this case, negative cerebrospinal fluid cultures and multiplex PCR made infection unlikely.
Imaging and diagnosis: MRI showed a longitudinally extensive, non-enhancing spinal cord lesion. With concurrent brain lesions suggestive of ICANS and infectious causes excluded, the authors considered ICANS-associated myelopathy the most likely diagnosis.
Treatment and uncertainty: Because severe encephalopathy limited neurological examination, the timing of spinal cord involvement was difficult to establish. The patient was treated for grade IV ICANS with high-dose corticosteroids and anakinra.
Key Findings:
Acute extensive myelopathy may occur after CAR T-cell therapy and may represent spinal cord involvement in ICANS.
A non-enhancing longitudinal spinal cord lesion is nonspecific; similar imaging findings have been described in limited reports of ICANS-associated myelopathy.
The authors report no definitive evidence supporting a specific treatment for ICANS-associated myelopathy, including immunoglobulins or plasmapheresis.
Interpretation:
The authors considered ICANS-associated myelopathy the most likely explanation in this case after infectious causes were rendered unlikely.
Limitations:
The timing of spinal cord involvement was difficult to determine because severe encephalopathy prevented a comprehensive neurological examination.
Evidence on diagnosis, treatment, and prognosis is limited; the authors state that larger series are needed.
